413 related articles for article (PubMed ID: 34193815)
1. Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M; Kantarjian H; Ravandi F
Blood Cancer J; 2021 Jun; 11(6):123. PubMed ID: 34193815
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
3. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
5. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
6. How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
Korsos V; Miller WH
J Mol Endocrinol; 2022 Nov; 69(4):T69-T83. PubMed ID: 36112505
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genomic characterization of an ATRA-insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion.
Kirkham JK; Liu YC; Foy SG; Ma J; Gheorghe G; Furtado LV; Popescu MI; Klco JM; Karol SE; Blackburn PR
Genes Chromosomes Cancer; 2023 Oct; 62(10):617-623. PubMed ID: 37283355
[TBL] [Abstract][Full Text] [Related]
9. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
10. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
11. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
Lauricella C; Greco R; Mancini V; Motta V; Ciraolo A; De Canal G; De Paoli E; Paglino G; Guido V; Bonoldi E; Veronese S; Soriani S
Acta Haematol; 2023; 146(1):58-64. PubMed ID: 36198282
[TBL] [Abstract][Full Text] [Related]
12. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
16. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
17. [State-of-the-art treatment of acute promyelocytic leukemia].
Kiguchi T
Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
Chen Y; Pan M; Chen L; Peng M; Liu Z; Fang Y; Du Y; Yang Y; Xu P
Ann Hematol; 2024 Apr; 103(4):1181-1185. PubMed ID: 38294534
[TBL] [Abstract][Full Text] [Related]
20. Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases.
Liu G; Liu L; Bartolo DD; Li KY; Li X
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
